Le Lézard
Classified in: Health, Covid-19 virus
Subjects: MAV, AVO

Media Advisory - Patients in the 'Fight for Our Lives' call on Parliament to STOP the PMPRB!


As the world comes together to fight coronavirus, Canadians with life-threatening rare and common diseases will march on Parliament Hill to ask for the same support in the 'Fight for Our Lives'

OTTAWA, March 9, 2020 /CNW/ - THE ISSUE: The federal government's draconian new patented drug pricing rules to be implemented by the Patented Medicine Prices Review Board (PMPRB) prevent life-saving treatments from coming to Canada. It's already happening ? remarkable new treatments for cystic fibrosis and sickle cell disease are now available elsewhere but haven't even been filed for approval here.

THE EVENT: The Canadian Organization for Rare Disorders (CORD) is leading a contingent of Canadian patients with rare and common diseases to Parliament Hill to "Fight for Our Lives" and to deliver one common message to their Members of Parliament: "Stop the PMPRB!" 

WHEN: Tuesday, March 10, 2020, at 12 pm

WHERE: Centennial Flame, Parliament Hill, Ottawa

Leaders of CORD and representatives of Canadians with cystic fibrosis and sickle cell disease are available to explain the crisis facing Canadian patients.

"The federal drug price controls are a death sentence for many patients." ? Chris McLeod, Chair of the Canadian Cystic Fibrosis Treatment Society and a CF patient.

"For decades, there have been no effective treatments for sickle cell disease. We now have a revolutionary new drug that can prevent the root cause of the disease, but it won't be made available to Canadians any time soon." ? Biba Tinga, President and Executive Director of the Sickle Cell Disease Association of Canada.

SOURCE Canadian Organization for Rare Disorders


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
Discovery Silver Corp. ("Discovery" or the "Company") today announced financial results for the three and twelve months ended December 31, 2023 ("Q4 2023" and "2023", respectively). The Company also provided a summary of key events since the...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...

28 mar 2024
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Will all...

28 mar 2024
Boat Rocker Media Inc. ("Boat Rocker" or the "Company") , an independent, integrated global entertainment company, today reported its financial results for the three months ended December 31, 2023 ("fourth quarter" or "Q4") and for the year ended...



News published on and distributed by: